Dataset Information

Sericin based nanoformulations: a comprehensive review on molecular mechanisms of interaction with organisms to biological applications.

ABSTRACT:

Background

The advances in products based on nanotechnology have directed extensive research on low-cost, biologically compatible, and easily degradable materials.

Main body

Sericin (SER) is a protein mainly composed of glycine, serine, aspartic acid, and threonine amino acids removed from the silkworm cocoon (particularly Bombyx mori and other species). SER is a biocompatible material with economic viability, which can be easily functionalized due to its potential crosslink reactions. Also, SER has inherent biological properties, which makes possible its use as a component of pharmaceutical formulations with several biomedical applications, such as anti-tumor, antimicrobials, antioxidants and as scaffolds for tissue repair as well as participating in molecular mechanisms attributed to the regulation of transcription factors, reduction of inflammatory signaling molecules, stimulation of apoptosis, migration, and proliferation of mesenchymal cells.

Conclusion

In this review, the recent innovations on SER-based nano-medicines (nanoparticles, micelles, films, hydrogels, and their hybrid systems) and their contributions for non-conventional therapies are discussed considering different molecular mechanisms for promoting their therapeutic applications.

SUBMITTER: Das G

PROVIDER: S-EPMC7821414 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Sericin based nanoformulations: a comprehensive review on molecular mechanisms of interaction with organisms to biological applications.

Das Gitishree G Shin Han-Seung HS Campos Estefânia V Ramos EVR Fraceto Leonardo Fernandes LF Del Pilar Rodriguez-Torres Maria M Mariano Kelli Cristina Freitas KCF de Araujo Daniele Ribeiro DR Fernández-Luqueño Fabián F Grillo Renato R Patra Jayanta Kumar JK

Journal of nanobiotechnology 20210122 1

<h4>Background</h4>The advances in products based on nanotechnology have directed extensive research on low-cost, biologically compatible, and easily degradable materials.<h4>Main body</h4>Sericin (SER) is a protein mainly composed of glycine, serine, aspartic acid, and threonine amino acids removed from the silkworm cocoon (particularly Bombyx mori and other species). SER is a biocompatible material with economic viability, which can be easily functionalized due to its potential crosslink react ...[more]

PMID: 33482828

Similar Datasets

Project description:Invasive lobular carcinoma (ILC) accounts for 10% to 15% of breast cancers in the United States, 80% of which are estrogen receptor (ER)-positive, with an unusual metastatic pattern of spread to sites such as the serosa, meninges, and ovaries, among others. Lobular cancer presents significant challenges in detection and clinical management given its multifocality and multicentricity at presentation. Despite the unique features of ILC, it is often lumped with hormone receptor-positive invasive ductal cancers (IDC); consequently, ILC screening, treatment, and follow-up strategies are largely based on data from IDC. Despite both being treated as ER-positive breast cancer, querying the Cancer Genome Atlas database shows distinctive molecular aberrations in ILC compared with IDC, such as E-cadherin loss (66% vs. 3%), FOXA1 mutations (7% vs. 2%), and GATA3 mutations (5% vs. 20%). Moreover, compared with patients with IDC, patients with ILC are less likely to undergo breast-conserving surgery, with lower rates of complete response following therapy as these tumors are less chemosensitive. Taken together, this suggests that ILC is biologically distinct, which may influence tumorigenesis and therapeutic strategies. Long-term survival and clinical outcomes in patients with ILC are worse than in stage- and grade-matched patients with IDC; therefore, nuanced criteria are needed to better define treatment goals and protocols tailored to ILC's unique biology. This comprehensive review highlights the histologic and clinicopathologic features that distinguish ILC from IDC, with an in-depth discussion of ILC's molecular alterations and biomarkers, clinical trials and treatment strategies, and future targets for therapy. IMPLICATIONS FOR PRACTICE: The majority of invasive lobular breast cancers (ILCs) are hormone receptor (HR)-positive and low grade. Clinically, ILC is treated similar to HR-positive invasive ductal cancer (IDC). However, ILC differs distinctly from IDC in its clinicopathologic characteristics and molecular alterations. ILC also differs in response to systemic therapy, with studies showing ILC as less sensitive to chemotherapy. Patients with ILC have worse clinical outcomes with late recurrences. Despite these differences, clinical trials treat HR-positive breast cancers as a single disease, and there is an unmet need for studies addressing the unique challenges faced by patients diagnosed with ILC.

Dataset Information

Sericin based nanoformulations: a comprehensive review on molecular mechanisms of interaction with organisms to biological applications.

Background

Main body

Conclusion

Publications

Sericin based nanoformulations: a comprehensive review on molecular mechanisms of interaction with organisms to biological applications.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets